D

Denali Therapeutics
D

DNLI

20.740
USD
-0.84
(-3.89%)
مغلق
حجم التداول
31,539
الربح لكل سهم
-3
العائد الربحي
-
P/E
-8
حجم السوق
2,984,934,482
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CRVS
    -0.22000
    (-4.99%)
    4.19000 USD
    I
    IMVT
    0.800
    (3.92%)
    21.230 USD
    I
    ITCI
    0.050
    (0.04%)
    128.580 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    V
    VIR
    -0.22000
    (-2.24%)
    9.58000 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Denali Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brainpenetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.